Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
|
|
Hepion Pharmaceuticals, Inc. (CTRV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/10/2020 |
8-K
| Appointed a new director|
Docs:
|
"Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors EDISON, N.J., June 10, 2020 - Hepion Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis , today announced that Dr. Peter Wijngaard has joined its Board of Directors. “Dr. Wijngaard provided invaluable guidance to Hepion’ s management team during our earlier work on cyclophilin inhibitors at Isotechnika Pharmaceuticals, Aurinia Pharmaceuticals, and Ciclofilin Pharmaceuticals, so we are thrilled to welcome him to our Board at this important point in Hepion’ s evolution,” said Dr. Robert Foster, Hepion’ s CEO. “With an exceptional amount of expe..." |
|
| 11/13/2018 |
8-K
| Appointed a new director |
| 12/15/2016 |
8-K
| Form 8-K - Current report |
| 09/21/2016 |
8-K
| Appointed a new director |
| 12/03/2015 |
8-K
| Appointed a new director |
| 11/27/2013 |
8-K
| Appointed a new director |
|
|